Disc Medicine Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of treatments for serious hematologic diseases. The company generates no product revenue as of its 10-K filed 2026-02-26, operating entirely on external financing while advancing a pipeline of clinical and preclinical drug candidates. Its pipeline targets fundamental biological pathways governing red blood cell formation and function, specifically heme biosynthesis and iron homeostasis. Lead candidate bitopertin is in clinical development for erythropoietic porphyrias (EPP and XLP), with a Phase 3 trial (APOLLO) aligned with the FDA following end-of-Phase 2 and Type C meetings in late 2024. DISC-0974 targets anemia of myelofibrosis and anemia of inflammatory bowel disease. DISC-3405 addresses polycythemia vera, sickle cell disease, and other hematologic disorders. Preclinical program DISC-0998 targets anemia associated with inflammatory diseases. Active collaborations include partnerships with Mabwell and the NIH.

Revenue model

Disc Medicine has no approved products and generates no product revenue as of the 10-K filed 2026-02-26. The company is funded through external financing while incurring research and development expenses across its clinical and preclinical programs.

Products and services

Pipeline includes: bitopertin (heme biosynthesis modulator, Phase 3-ready for EPP and XLP, with ongoing long-term extension study HELIOS); DISC-0974 (iron homeostasis, clinical-stage, targeting anemia of myelofibrosis and anemia of inflammatory bowel disease); DISC-3405 (clinical-stage, targeting polycythemia vera, sickle cell disease, and other hematologic disorders); DISC-0998 (preclinical, targeting anemia associated with inflammatory diseases).

Customers and end markets

Target patient populations include those with erythropoietic porphyrias (EPP, XLP), anemia of myelofibrosis, anemia of inflammatory bowel disease, polycythemia vera, sickle cell disease, and inflammatory anemia. No commercial customers as of the 10-K filed 2026-02-26.

Value-chain role

Clinical-stage drug developer. Relies on third-party contract manufacturers for preclinical and clinical-stage production. Conducts clinical trials at external sites including locations in the United States and Australia.

Geographic exposure

Clinical trials conducted in the United States and Australia as referenced in the 10-K filed 2026-02-26. Regulatory engagement primarily with the U.S. FDA.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: Akebia Therapeutics Inc X4 Pharmaceuticals Inc Atreca, Inc. Senti Biosciences Inc ImmuCell Corp EOM Pharmaceutical Holdings, Inc. Palatin Technologies Inc Surface Oncology, Inc. Solid Biosciences Inc